Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 81 out of 100. Clinical trials

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

EVOKE (ClinicalTrials.gov NCT04777396) and EVOKE+ (NCT04777409) tested whether oral semaglutide, the GLP-1 diabetes/weight-loss drug, could slow early Alzheimer's disease progression in a combined 3,808 participants over up to 156 weeks. Neither trial showed a benefit on the main measure of decline (CDR-SB): the difference from placebo was essentially zero in both studies. Semaglutide did modestly lower some brain-inflammation and tau biomarkers in spinal fluid/blood, but this did not translate into any detectable slowing of cognitive or functional decline, and side effects (nausea, appetite loss, weight loss) were more common than with placebo. Novo Nordisk ended its Alzheimer's program for semaglutide after this result.

What this study adds

Evidence grade: Null result

The record lists 3,808 participants. In two Phase 3 trials of 3,808 participants, oral semaglutide showed no significant difference from placebo in clinical decline on the main measure, and Novo Nordisk ended its Alzheimer's program for the drug after this result. Reported effect size: EVOKE difference -0.08 (95% CI -0.35 to 0.20); EVOKE+ difference 0.10 (95% CI -0.17 to 0.38).

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Cummings, J. L., Atri, A., Scheltens, P., et al. (2026). Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (EVOKE and EVOKE+): two phase 3, randomised, placebo-controlled trials. The Lancet. https://doi.org/10.1016/s0140-6736(26)00459-9

Vancouver

Cummings JL, Atri A, Scheltens P, et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (EVOKE and EVOKE+): two phase 3, randomised, placebo-controlled trials. The Lancet. 2026. doi:10.1016/s0140-6736(26)00459-9. PMID: 41865758.

BibTeX

@article{cummings2026-c800c391,
  author  = {Cummings, J. L. and Atri, A. and Scheltens, P. and others},
  title   = {{Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (EVOKE and EVOKE+): two phase 3, randomised, placebo-controlled trials}},
  journal = {The Lancet},
  year    = {2026},
  doi     = {10.1016/s0140-6736(26)00459-9},
  pmid    = {41865758},
  url     = {https://doi.org/10.1016/s0140-6736(26)00459-9}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In two Phase 3 trials of 3,808 participants, oral semaglutide showed no significant difference from placebo in clinical decline on the main measure, and Novo Nordisk ended its Alzheimer's program for the drug after this result. Some biomarker reductions did not translate into any detectable slowing of cognitive or functional decline.

Study details

Limitations

Definitively null result on the primary clinical endpoint despite large size; conducted only in already-symptomatic AD, so it doesn't address earlier preventive use; more GI adverse events (91.2% vs. 84.8%) with semaglutide.

How this study scored 81/100
How this study's score is builtJournal tier 10 of 10; Journal's citation record left out, no data; Study design 11 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 3 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 2 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here 0 of 6; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 0 of 2; Free to read left out, no data. 50 of the 62 points it could be judged on, which is 81 of 100. Total 81 of 100.50 of the 62 points we could judge = 81 of 100

Published in a top-tier journal, and it is a large phase 3 trial. Scored zero for indexed in PubMed because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 50 of the 62 points we could judge it on, which is 81 out of 100.

ComponentPointsWhy
Journal tier 10 / 10 Tier 1 — top-tier general journal (The Lancet)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 11 / 12 A large phase 3 trial
Strength of evidence 3 / 5 Rated “null-result” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 3 / 4 3,808 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 2 / 2 Randomized and blinded or placebo-controlled (as stated in the record)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 0 / 2 No PubMed ID and no DOI — scores zero (not stated in the record — scored 0)
Free to read — / 2 Access not recorded — left out of this score
Points 50 / 62 Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 50 of the 62 points we could judge it on is 81 out of 100.
Total 81 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Clinical trials from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Clinical trials

See all studies in Clinical trials →